Medical Oncologist
Hormone receptor-positive breast cancer means the cancer cells carry receptors for estrogen (ER) and/or progesterone (PR), so their growth is fuelled by these hormones. It is by far the most common breast cancer subtype — around 70–80% of all breast cancers are hormone-receptor-positive. The good news is that this gives doctors a clear target: endocrine (hormone) therapy can switch off that fuel. Most HR+ cancers (the large luminal A and B group) are HER2-negative and tend to be slower-growing with a generally better outlook. At CION, a woman-headed, tumour-board-led team builds an accurate, IHC-based plan for ER/PR+ breast cancer.
Hormone receptor-positive breast cancer is a cancer whose cells carry receptors for estrogen (ER) and/or progesterone (PR) on their surface. These receptors act like docking points: when the body's natural hormones attach to them, they signal the cancer cells to grow. In other words, the cancer's growth is fuelled by hormones. This is established by testing the tissue from a breast biopsy — the same report that guides all breast cancer treatment.
This is the most common breast cancer subtype: around 70–80% of all breast cancers are hormone-receptor-positive (HR+). The presence of a hormone target is genuinely good news, because it means a whole category of effective, well-tolerated treatment — endocrine (hormone) therapy — can be used to switch off the fuel supply. Most HR+ cancers are also HER2-negative; these form the large luminal A and luminal B groups that tend to grow more slowly than other subtypes.
Most breast cancers are hormone-receptor-positive. Because growth depends on estrogen and/or progesterone, treatment can target that hormone supply directly.
"Hormone receptor-positive" describes the biology of the cancer (its receptor status), not how advanced it is. An ER/PR+ cancer can be early-stage or advanced — subtype and stage are separate things.
ER/PR status comes from IHC testing on the biopsy, alongside HER2 status, tumour grade and Ki67 — together these define the subtype and shape the plan.
Around 70–80% of all breast cancers are hormone-receptor-positive, making ER/PR+ disease by far the most common subtype. Unlike faster-growing cancers, HR+ breast cancer can recur years — even a decade — after the original treatment, which is exactly why endocrine (hormone) therapy is taken for 5 to 10 years rather than a few months. Source: NCCN Breast Cancer guidance; SEER; ICMR/NCRP.
"Hormone receptor-positive" is not a single thing — it covers a few combinations, and the exact mix changes the treatment plan. Every biopsy reports three results: the estrogen receptor (ER), the progesterone receptor (PR), and the HER2 protein. A cancer is called hormone-receptor-positive if ER and/or PR is positive. What also matters is whether HER2 is negative or positive — because that splits HR+ disease into two very different treatment groups.
Understanding your exact combination helps explain why your plan may differ from another woman's, even though you both have "hormone-positive breast cancer". The overlap with the luminal subtypes is almost complete: luminal A and luminal B are simply the names pathologists give to these HR+ groups.
The most favourable combination: both hormone receptors are present. These cancers usually respond best to endocrine (hormone) therapy and tend to be slower-growing — the classic luminal A pattern when HER2 is negative and grade is low.
Estrogen-receptor positive but progesterone-receptor negative. This is still hormone-receptor-positive and still treated with endocrine therapy, but it can behave a little more assertively than ER+/PR+ disease.
By far the largest group — the luminal A and B cancers. Endocrine therapy is the backbone; higher-risk cases may add CDK4/6 inhibitors. Most HR+ cancers fall here.
Hormone receptors are positive and HER2 is also overexpressed. These need both endocrine therapy and HER2-targeted therapy — a combined plan covered in detail on our HER2-positive page.
Receptor status is not guessed from a scan — it is measured directly on the cancer tissue. After a core needle biopsy, the laboratory runs immunohistochemistry (IHC), a stain that shows whether the cancer cells carry estrogen and progesterone receptors and how strongly. The same workup checks HER2 status, tumour grade and Ki67 — together these four results define your subtype and the plan that follows.
You will often see ER and PR reported as a percentage of positive cells, sometimes with a combined score (for example an Allred score or an H-score). The exact number matters less than the principle: even a low-but-positive ER result usually still makes endocrine therapy worthwhile.
IHC reports the proportion of cancer cells that stain positive for estrogen and progesterone receptors. A higher percentage generally predicts a stronger response to hormone therapy, but even low positivity counts as ER/PR-positive.
These are simply combined scores that fold together how many cells are positive and how intensely they stain, giving the oncologist a single, comparable measure of receptor strength.
Checked at the same time. HER2-negative HR+ cancers are the luminal A/B group; HER2-positive HR+ cancers need added HER2-targeted treatment.
Grade describes how abnormal the cells look; Ki67 estimates how fast they divide. Together they help separate slower luminal A cancers from the more proliferative luminal B pattern — and guide whether to add more treatment.
Because HR+ cancer is driven by hormones, the central treatment is endocrine (hormone) therapy — medicines that block estrogen's effect on the cancer or lower estrogen levels in the body. This is usually given as a daily tablet for 5 to 10 years after surgery, and which drug is chosen depends largely on whether you are pre- or postmenopausal. Surgery, radiation and (for some) chemotherapy still have their place, but endocrine therapy is what keeps HR+ cancer suppressed over the long term.
This same therapy is the backbone described on our luminal breast cancer page, since the luminal subtypes are simply the HR+ cancers in another name.
Tamoxifen blocks estrogen from attaching to the receptor and works regardless of whether the ovaries are still producing estrogen. It is the usual choice for younger, pre- and perimenopausal women, taken daily for several years.
After menopause, the body makes estrogen in fat and other tissues using an enzyme called aromatase. Aromatase inhibitors block this enzyme to lower estrogen, and are the usual choice for postmenopausal women.
For some higher-risk premenopausal women, switching off the ovaries' estrogen output — temporarily with medication or permanently — lets an aromatase inhibitor be used and adds extra protection.
HR+ cancer can come back late, so long endocrine therapy keeps suppressing any stray cells for years. The exact length is tailored to your risk, and we manage side effects so you can stay the course.
HR+ breast cancer is highly treatable, but the long-term nature of the plan — years of endocrine therapy, careful monitoring for late recurrence, and decisions about adding CDK4/6 inhibitors — is exactly where a full team adds value. CION is a woman-headed, tumour-board-led organisation that gets the subtype right and supports you through years of treatment, not just the first few weeks.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Woman-led, tumour-board-reviewed, IHC-based care for hormone receptor-positive breast cancer across 35+ centres in Telangana & AP. Call 1800-202-8726.
For most early HR+/HER2-negative cancers, endocrine therapy alone does the heavy lifting. But for higher-risk early disease and for advanced (metastatic) HR+ cancer, oncologists add a class of targeted tablets called CDK4/6 inhibitors to the hormone therapy. These block proteins the cancer cells use to divide, and combining them with endocrine therapy has improved outcomes in this group.
Chemotherapy is used more selectively in HR+ disease than in triple-negative cancer. When grade, Ki67 or genomic testing suggest a real benefit, targeted treatment and chemotherapy are layered on by the tumour board — so you get more treatment only when it genuinely helps.
Endocrine therapy is far gentler than chemotherapy, but because it works by reducing estrogen's effect, it can bring menopause-type symptoms. These are usually manageable, and managing them well matters — staying on the tablet for the full course is one of the most important things you can do for a HR+ cancer. Our dedicated hormone therapy side effects guide goes into more depth, and a few simple steps make a real difference.
The pattern of effects differs between tamoxifen and aromatase inhibitors, which is one reason your oncologist tailors the choice to you — and can switch you if a particular drug does not suit.
Compared with triple-negative breast cancer, HR+/HER2-negative cancer is generally slower-growing and carries a more favourable outlook, especially when it is found early. Many early-stage HR+ cancers are treated with the goal of cure, and a large proportion of women are cured. The trade-off is a distinctive pattern: HR+ cancer has a lower early peak of recurrence but a longer tail — it can come back five, ten or more years after the original treatment.
This late-recurrence risk is exactly why endocrine therapy is taken for so long, and why follow-up care continues for years. Your own outlook depends on stage, grade, Ki67 and how well treatment suits you — not on averages alone. At CION, 1-year survival outcomes for breast cancer run meaningfully ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
If you have read about luminal breast cancer, you have essentially been reading about hormone receptor-positive cancer under a different name. "Luminal" is the term pathologists use for HR+ cancers based on their cell-of-origin pattern, and the two groups overlap almost completely. Luminal A and luminal B are simply subdivisions of HR+ disease.
Knowing which luminal pattern you fall into helps explain how much treatment you need. Our luminal breast cancer page covers these subtypes in more detail; the essentials are below.
A hormone-positive diagnosis is highly treatable, but the plan stretches over years — so getting it right from the start matters. CION offers a clear, woman-led pathway from first consultation through long-term follow-up, built around your exact receptor status, menopause stage and risk — with your first consultation free.
A specialist reviews your biopsy and IHC report in full, explains what ER/PR-positive means for you, and outlines the likely plan — no rushed decisions, no unnecessary tests.
We confirm ER/PR percentages, HER2 status, grade and Ki67 to place you correctly in the luminal A/B framework — up to 50% discounts on diagnostics where applicable.
3+ oncologists plan your treatment together — surgery, radiation where needed, the right endocrine therapy for your menopause status, and CDK4/6 inhibitors or chemotherapy only when they clearly help.
We help you stay on endocrine therapy through the full course, manage side effects, and watch for late recurrence — with nutrition, psycho-oncology and transparent costs throughout.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Talk to our team
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
It means the cancer cells carry receptors for estrogen (ER) and/or progesterone (PR) — docking points that let these hormones signal the cells to grow. In simple terms, the cancer is fuelled by hormones. This is the most common type of breast cancer: around 70–80% of all breast cancers are hormone-receptor-positive. The big advantage is that the cancer has a clear, treatable target — endocrine (hormone) therapy can block estrogen or lower its levels and slow or stop growth. Receptor status is measured by IHC testing on the biopsy, which also reports HER2 status, grade and Ki67 to define the exact subtype.
Essentially, yes — they are two names for largely the same group. "Luminal" is the term pathologists use for hormone receptor-positive cancers, divided into luminal A and luminal B based on grade, Ki67 and HER2 status. Luminal A cancers are strongly ER/PR-positive, HER2-negative, low grade and slow-growing, and usually respond very well to hormone therapy. Luminal B cancers are still hormone-positive but more proliferative, and may need CDK4/6 inhibitors or chemotherapy added. So if you have read about luminal breast cancer, you have been reading about HR+ disease. Our luminal breast cancer page covers these subtypes in more depth.
Receptor status is measured directly on the cancer tissue, not from a scan. After a core needle biopsy, the laboratory runs immunohistochemistry (IHC) — a stain that shows whether the cancer cells carry estrogen and progesterone receptors and how strongly. ER and PR are usually reported as a percentage of positive cells, sometimes summarised as an Allred score or H-score that combines how many cells are positive with how intensely they stain. The same workup checks HER2 status, grade and Ki67. Even a low-but-positive ER result generally still makes endocrine therapy worthwhile, so the precise number matters less than whether it is positive.
The backbone is endocrine (hormone) therapy — tablets that block estrogen or lower its levels. The choice depends on your menopause status: tamoxifen is the usual option for pre- and perimenopausal women, while aromatase inhibitors are used after menopause. For some higher-risk premenopausal women, ovarian suppression is added. This treatment is usually taken for 5 to 10 years. Surgery and, where needed, radiation treat the local cancer, and for higher-risk or advanced HR+/HER2-negative disease, CDK4/6 inhibitors are added to the hormone therapy. Chemotherapy is used more selectively than in triple-negative cancer, only when grade, Ki67 or genomic tests show a clear benefit.
Hormone receptor-positive breast cancer has a distinctive pattern: it can recur late, sometimes five, ten or more years after the original treatment. Long endocrine therapy keeps suppressing any stray cancer cells over that long window, which lowers the chance of late recurrence. Studies show that extending hormone therapy benefits many women, so oncologists tailor the length to your individual risk. Completing the full course is one of the most protective things you can do for your long-term outlook. Because the tablets are taken for years, managing side effects well is important — and if a particular drug does not suit you, switching is almost always possible.
Endocrine therapy is much gentler than chemotherapy, but because it reduces estrogen, it can cause menopause-type symptoms: hot flushes, night sweats, mood changes and reduced libido. Aromatase inhibitors can cause joint stiffness and gradual bone thinning, so bone density is monitored. Tamoxifen carries a small increased risk of blood clots and changes to the uterine lining, so any unusual bleeding should be reported. Most effects are manageable, and for the great majority of women the benefit far outweighs the risks. Our hormone therapy side effects guide has more detail, and our team helps you stay on treatment for the full course.
Generally, yes. HR+/HER2-negative cancer — the large luminal A/B group — tends to be slower-growing and carries a more favourable outlook than triple-negative breast cancer, especially when found early. Many early-stage HR+ cancers are treated with the goal of cure, and a large proportion of women are cured. The important caveat is the risk of late recurrence: HR+ cancer can come back years later, which is why endocrine therapy and follow-up continue for so long. Advanced (metastatic) HR+ disease is generally not curable but is very treatable — endocrine therapy with CDK4/6 inhibitors can control it and extend good-quality life, often for years.
Yes. CION offers a free first consultation for all cancer patients, including women newly diagnosed with ER/PR-positive breast cancer or seeking a second opinion. It is a full 45-minute consultation — a specialist reviews your biopsy and IHC report, explains your exact receptor status and luminal subtype, recommends the right endocrine therapy for your menopause status, advises on CDK4/6 inhibitors or surgery where relevant, and gives you a clear, tumour-board-backed plan. There are no rushed decisions and no unnecessary tests, and CION offers up to 50% discounts on diagnostics. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.